Melanoma (Skin) Clinical Trial
Official title:
Effectiveness of Group and Individual Training in Emotional Freedom Techniques for Patients in Remission From Melanoma
Verified date | April 2024 |
Source | Soul Medicine Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Serious medical diagnosis frequently induce fear focused on specific anticipations or generalized anxiety, along with uncertainty, insecurity, and disorientation. Other emotions such as anger, depression, hopelessness, shame, or grief may also become involved following a serious diagnosis. The adverse impact of stress on health and immune function is well-established, as well as its link to depression and anxiety. Emotional Freedom Techniques (EFT) has demonstrated efficacy in treating anxiety, depression, and PTSD. This study tests its effectiveness in reducing negative emotional symptoms in general, and fear of recurrence in particular, among individuals previously diagnosed with melanoma and currently in remission.
Status | Active, not recruiting |
Enrollment | 57 |
Est. completion date | July 20, 2027 |
Est. primary completion date | July 20, 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Melanoma diagnosis over six months prior to the study; confirmed by clinical, dermoscopic examination and pathology results Exclusion Criteria: - In active treatment for melanoma - schizophrenia - epilepsy - other malignant disease |
Country | Name | City | State |
---|---|---|---|
Israel | The School Of Social Work Tel Aviv University | Tel Aviv |
Lead Sponsor | Collaborator |
---|---|
Soul Medicine Institute | Tel Aviv University |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Illness perception | Change in score on Revised Illness Perception Questionnaire (IPQ-R) | Pre intervention, post 4 week intervention, and 3 month follow-up | |
Primary | Perception of recurrence | Change of perceived recurrence risk on a Likert scale | Pre intervention, post 4 week intervention, and 3 month follow-up | |
Secondary | Other physical symptoms | Change in patient's self-report of somatization, pain, and other symptoms on a Likert scale | Pre intervention, post 4 week intervention, and 3 month follow-up | |
Secondary | Depression | Change in depressive symptoms on the Positive and Negative Affect Schedule (PANAS) | Pre intervention, post 4 week intervention, and 3 month follow-up | |
Secondary | Anxiety | Change in anxiety symptoms on the Positive and Negative Affect Schedule (PANAS) | Pre intervention, post 4 week intervention, and 3 month follow-up | |
Secondary | Patient's self-report of quality of life | Change in quality of life scores on the Quality of Life Scale (QOLS) | Pre intervention, post 4 week intervention, and 3 month follow-up | |
Secondary | Wellbeing | Change in score on The Well-being Numerical Rating Scales (WB-NRSs). | Pre intervention, post 4 week intervention, and 3 month follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04062032 -
Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma
|
Phase 2 | |
Completed |
NCT03620019 -
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT03291002 -
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
|
Phase 1 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Completed |
NCT00962845 -
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
|
Early Phase 1 | |
Completed |
NCT00324623 -
Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma
|
Phase 1 | |
Completed |
NCT00104845 -
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
|
Phase 1 | |
Completed |
NCT00096382 -
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00072124 -
Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma
|
Phase 3 | |
Completed |
NCT00089193 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00072085 -
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT00039234 -
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
|
Phase 3 | |
Completed |
NCT00049010 -
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
|
N/A | |
Completed |
NCT00042783 -
Vaccine Therapy in Treating Patients With Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00005610 -
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
|
Phase 2 | |
Completed |
NCT00006022 -
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
|
Phase 1 | |
Completed |
NCT00006385 -
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00020358 -
Vaccine Therapy in Treating Patients With Melanoma
|
Phase 2 | |
Recruiting |
NCT03767348 -
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
|
Phase 2 | |
Withdrawn |
NCT00006126 -
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
|
Phase 1 |